Oncotarget

Research Papers:

A comparative study of anti-aging properties and mechanism: resveratrol and caloric restriction

Juan Li, Chun-Xia Zhang, Yi-Mei Liu, Ke-Li Chen and Gang Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:65717-65729. https://doi.org/10.18632/oncotarget.20084

Metrics: PDF 2708 views  |   HTML 4654 views  |   ?  


Abstract

Juan Li1, Chun-Xia Zhang1, Yi-Mei Liu1, Ke-Li Chen1 and Gang Chen1,2

1Key Laboratory of Ministry of Education on Traditional Chinese Medicine Resource and Compound Prescription, Hubei University of Chinese Medicine, Wuhan 430065, Hubei, China

2Hubei College of Chinese Medicine, Jingzhou 434020, Hubei, China

Correspondence to:

Gang Chen, email: [email protected]

Keywords: resveratrol, caloric restriction, SIRT1, aging

Received: June 12, 2017     Accepted: July 25, 2017     Published: August 09, 2017

ABSTRACT

Resveratrol and caloric restriction (CR) are the powerful therapeutic options for anti-aging. Here, their comparative effect on longevity-associated gene silencing information regulator (SIRT1) were evaluated in vitro and in vivo. IMR-90 cells treated with 2,2’-azobis (2-amidinopropane) dihydrochloride (AAPH) were applied to establish a cellular senescence model, and rats treated with D-galactose (D-gal) were used as an aging animal model. Resveratrol and CR exhibited similar anti-aging activities, evidenced by inhibiting senescence and apoptosis, and restoring cognitive impairment and oxidative damage. Moreover, they could up-regulate telomerase (TE) activity, increase expressions of SIRT1, forkhead box 3a (Foxo3a), active regulator of SIRT1 (AROS) and Hu antigen R (HuR ), but decrease p53 and deleted in breast cancer 1 (DBC1) levels. However, 10 μM resveratrol in vitro and the high dose group in vivo showed relatively stronger activities of anti-aging and stimulating SIRT1 level than CR. In conclusion, resveratrol and CR showed similar anti-aging activities on SIRT1 signaling, implicating the potential of resveratrol as a CR mimetic.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20084